US2012252761A1PendingUtilityA1

Kinase inhibitors

50
Individually held — no corporate assignee on recordPriority: Apr 18, 2007Filed: Apr 2, 2012Published: Oct 4, 2012
Est. expiryApr 18, 2027(~0.7 yrs left)· nominal 20-yr term from priority
Inventors:Jason W. BrownQing DongBheema R. ParaselliNicholas ScorahJeffrey Alan StaffordMichael B. WallaceHasanthi Wijesekera
A61P 35/00A61P 43/00A61P 25/28A61P 25/16A61P 25/00A61P 29/00A61P 19/02C07D 487/04C07D 471/04C07D 471/14C07D 241/18C07D 401/12
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Claims

exact text as granted — not AI-modified
1 - 92 . (canceled) 
     
     
         93 . The compound 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof. 
     
     
         94 . A pharmaceutical composition comprising the compound 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof and a pharmaceutically excipient.

Join the waitlist — get patent alerts

Track US2012252761A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.